International Aids Vaccine Initiative Inc
- Assets
- $107.0m
- Revenue
- $126.4m
- Investments
- $0.0
- Employees
- 227
- Location
- New York, NY
- Founding
- 07/1996
- Data as of
- 12/2021
- EIN
- 13-3870223
Organization Overview
International Aids Vaccine Initiative Inc, operating under the name Iavi, is located in New York, NY. The organization was established in 1996. According to its NTEE Classification (Q30) the organization is classified as: International Development, under the broad grouping of International, Foreign Affairs & National Security and related organizations. As of 12/2021, Iavi employed 227 individuals. This organization is an independent organization and not affiliated with a larger national or regional group of organizations. Iavi is a 501(c)(3) and as such, is described as a "Charitable or Religous organization or a private foundation" by the IRS.
For the year ending 12/2021, Iavi generated $126.4m in total revenue. This represents relatively stable growth, over the past 7 years the organization has increased revenue by an average of 8.3% each year. All expenses for the organization totaled $113.2m during the year ending 12/2021. While expenses have increased by 7.6% per year over the past 7 years. They've been increasing with an increasing level of total revenue. You can explore the organizations financials more deeply in the financial statements section below.
Since 2015, Iavi has awarded 105 individual grants totaling $41,849,059. If you would like to learn more about the grant giving history of this organization, scroll down to the grant profile section of this page.
Form
990
Mission & Program ActivityExcerpts From the 990 Filing
TAX YEAR
2021
Describe the Organization's Mission:
Part 3 - Line 1
TRANSLATE SCIENTIFIC DISCOVERIES INTO AFFORDABLE, GLOBALLY ACCESSIBLE PUBLIC HEALTH SOLUTIONS
Describe the Organization's Program Activity:
Part 3 - Line 4a
RESEARCH AND DEVELOPMENT: THROUGH SCIENTIFIC AND CLINICAL RESEARCH IN AFRICA, INDIA, EUROPE, AND THE U.S., IAVI DEVELOPS VACCINES AND ANTIBODIES IN AND FOR THE DEVELOPING WORLD AND SEEKS TO ACCELERATE THEIR INTRODUCTION IN LOW-INCOME COUNTRIES. IAVI ADVANCES SCIENTIFIC DISCOVERY AND DEVELOPMENT BY FOSTERING UNIQUE COLLABORATIONS AMONG ACADEMIA, INDUSTRY, LOCAL COMMUNITIES, GOVERNMENTS, AND FUNDERS TO EXPLORE NEW AND BETTER WAYS TO ADDRESS PUBLIC HEALTH THREATS THAT DISPROPORTIONATELY AFFECT PEOPLE LIVING IN POVERTY. VACCINE AND ANTIBODY CANDIDATES ARE PUT THROUGH A RIGOROUS PROCESS OF CLINICAL EVALUATION AMONG KEY POPULATIONS TO ESTABLISH THEIR SAFETY AND EFFICACY, AN EFFORT THAT ENABLES IAVI TO STRENGTHEN THE HEALTHCARE INFRASTRUCTURE AND SCIENTIFIC CAPACITY OF COUNTRIES WHERE OUR CLINICAL PARTNERS OPERATE. TO DATE, IAVI AND ITS PARTNERS HAVE ADVANCED DOZENS OF HIV VACCINE CANDIDATES INTO EARLY STAGE CLINICAL TRIALS. THIS INCLUDES THE FIRST HIV VACCINE TRIALS IN SUB-SAHARAN COUNTRIES, WHERE THE HIV BURDEN IS GREATEST. IAVI HAS CONDUCTED MORE THAN 50 EPIDEMIOLOGICAL STUDIES AND PROVIDED VOLUNTARY HIV TESTING, COUNSELING SERVICES, AND HEALTH CARE REFERRALS TO MORE THAN 870,000 INDIVIDUALS IN AFRICA. IAVI ALSO SUPPORTS PRECLINICAL DEVELOPMENT AND CLINICAL TESTING OF VACCINE CANDIDATES FOR OTHER DISEASES, INCLUDING TUBERCULOSIS, LASSA FEVER AND COVID-19, AS WELL AS ANTIBODY CANDIDATES FOR DISEASE PREVENTION AND TREATMENT. IAVI CONDUCTS TRIALS WITH THE HIGHEST SCIENTIFIC AND ETHICAL STANDARDS TO PROTECT THE RIGHTS, WELL-BEING, AND DIGNITY OF TRIAL VOLUNTEERS. IAVI HAS ALSO LAUNCHED RESEARCH CONSORTIA TO ADDRESS MAJOR SCIENTIFIC PROBLEMS OF BIOMEDICAL PRODUCT DEVELOPMENT. A SIGNIFICANT PORTION OF THE RESEARCH IAVI SUPPORTS IS CONDUCTED IN DEVELOPING COUNTRIES WHERE THE NEED FOR INFECTIOUS DISEASE PREVENTION IS GREATEST.
CONTRACT MANUFACTURING-RELATED ACTIVITIES: IAVI SUPPORTS EXTERNAL RESEARCHERS BY PROVIDING TECHNICAL AND SCIENTIFIC EXPERTISE TO ACCELERATE THE DEVELOPMENT OF THEIR OWN PRODUCTS.
VACCINE ADVOCACY, PUBLIC AFFAIRS, AND POLICY: IAVI WORKS WITH POLICY MAKERS, ADVOCATES, AND REPRESENTATIVES OF THE COMMUNITIES WHERE DISEASE BURDEN IS GREATEST TO SUPPORT SCIENTIFIC RESEARCH AND DEVELOPMENT FOR ACCESSIBLE BIOMEDICAL PREVENTIVES AND TREATMENTS.
Get More from Intellispect for FreeCreate a free account to get more data, nonprofit salaries, advanced search and more.
Board, Officers & Key Employees
| Name (title) | Role | Hours | Compensation |
|---|---|---|---|
Mark Feinberg President/ceo | OfficerTrustee | 35 | $646,997 |
Ana Cespedes Montoya Chief Operating Officer | Officer | 35 | $509,916 |
Christopher Parks Executive Dir., Viral Vaccinces | 35 | $464,753 | |
Swati Gupta Vp, Eid & Scientific Strategy | 35 | $435,928 | |
Thomas Hassell Vp, Vaccine Development R&d | 35 | $396,671 | |
Louis Schwartz Asst. Sec. & Chief Financial Officer | Officer | 35 | $368,299 |
Outside Vendors & Contractors
| Vendor Name (Service) | Service Year | Compensation |
|---|---|---|
Emmes Corporation Clinical Research Studies | 12/30/21 | $1,145,073 |
Australian Biologics Pty Ltd Regulatory Consultant | 12/30/21 | $406,450 |
Us Medical Equipment Consultants Inc Equipment Maintenance | 12/30/21 | $344,333 |
Stradley Ronon Stevens & Young Llp Legal Services | 12/30/21 | $276,568 |
Duane Morris Llp Legal Services | 12/30/21 | $251,941 |
Financial Statements
| Statement of Revenue | |
|---|---|
| Federated campaigns | $0 |
| Membership dues | $0 |
| Fundraising events | $0 |
| Related organizations | $0 |
| Government grants | $77,633,796 |
| All other contributions, gifts, grants, and similar amounts not included above | $46,780,880 |
| Noncash contributions included in lines 1a–1f | $0 |
| Total Revenue from Contributions, Gifts, Grants & Similar | $124,414,676 |
| Total Program Service Revenue | $1,706,926 |
| Investment income | $613,689 |
| Tax Exempt Bond Proceeds | $0 |
| Royalties | $0 |
| Net Rental Income | $0 |
| Net Gain/Loss on Asset Sales | -$553,801 |
| Net Income from Fundraising Events | $0 |
| Net Income from Gaming Activities | $0 |
| Net Income from Sales of Inventory | $0 |
| Miscellaneous Revenue | $0 |
| Total Revenue | $126,352,598 |
| Statement of Expenses | |
|---|---|
| Grants and other assistance to domestic organizations and domestic governments. | $7,079,271 |
| Grants and other assistance to domestic individuals. | $0 |
| Grants and other assistance to Foreign Orgs/Individuals | $19,297,560 |
| Benefits paid to or for members | $0 |
| Compensation of current officers, directors, key employees. | $2,402,142 |
| Compensation of current officers, directors, key employees. | $2,230,806 |
| Compensation to disqualified persons | $0 |
| Other salaries and wages | $30,069,602 |
| Pension plan accruals and contributions | $2,155,033 |
| Other employee benefits | $3,472,726 |
| Payroll taxes | $1,823,966 |
| Fees for services: Management | $0 |
| Fees for services: Legal | $694,102 |
| Fees for services: Accounting | $206,275 |
| Fees for services: Lobbying | $247,500 |
| Fees for services: Fundraising | $0 |
| Fees for services: Investment Management | $88,275 |
| Fees for services: Other | $764,774 |
| Advertising and promotion | $0 |
| Office expenses | $802,164 |
| Information technology | $1,785,621 |
| Royalties | $0 |
| Occupancy | $2,858,766 |
| Travel | $185,820 |
| Payments of travel or entertainment expenses for any federal, state, or local public officials | $0 |
| Conferences, conventions, and meetings | $218,770 |
| Interest | $9,393 |
| Payments to affiliates | $0 |
| Depreciation, depletion, and amortization | $1,393,883 |
| Insurance | $353,209 |
| All other expenses | $94,270 |
| Total functional expenses | $113,151,683 |
| Balance Sheet | |
|---|---|
| Cash—non-interest-bearing | $0 |
| Savings and temporary cash investments | $35,825,161 |
| Pledges and grants receivable | $33,286,783 |
| Accounts receivable, net | $891,734 |
| Loans from Officers, Directors, or Controlling Persons | $0 |
| Loans from Disqualified Persons | $0 |
| Notes and loans receivable | $0 |
| Inventories for sale or use | $0 |
| Prepaid expenses and deferred charges | $198,282 |
| Net Land, buildings, and equipment | $3,887,856 |
| Investments—publicly traded securities | $32,733,205 |
| Investments—other securities | $0 |
| Investments—program-related | $0 |
| Intangible assets | $0 |
| Other assets | $226,002 |
| Total assets | $107,049,023 |
| Accounts payable and accrued expenses | $7,483,619 |
| Grants payable | $10,451,288 |
| Deferred revenue | $35,515,982 |
| Tax-exempt bond liabilities | $0 |
| Escrow or custodial account liability | $0 |
| Loans and other payables to any current Officer, Director, or Controlling Person | $0 |
| Secured mortgages and notes payable | $0 |
| Unsecured mortgages and notes payable | $0 |
| Other liabilities | $2,627,839 |
| Total liabilities | $56,078,728 |
| Net assets without donor restrictions | $39,462,629 |
| Net assets with donor restrictions | $11,507,666 |
| Capital stock or trust principal, or current funds | $0 |
| Paid-in or capital surplus, or land, building, or equipment fund | $0 |
| Retained earnings, endowment, accumulated income, or other funds | $0 |
| Total liabilities and net assets/fund balances | $107,049,023 |
Grants Awarded
Over the last fiscal year, International Aids Vaccine Initiative Inc has awarded $7,079,271 in support to 19 organizations.
| Grant Recipient | Amount |
|---|---|
La Jolla, CA PURPOSE: RESEARCH & DEVELOPMENT | $2,550,777 |
Atlanta, GA PURPOSE: RESEARCH & DEVELOPMENT | $771,785 |
THE UNIVERSITY OF TEXAS MEDICAL BRANCH GALVESTON PURPOSE: RESEARCH & DEVELOPMENT | $695,075 |
UNIVERSITY OF WISCONSIN-MADISON PURPOSE: RESEARCH & DEVELOPMENT | $482,328 |
Somerville, MA PURPOSE: RESEARCH & DEVELOPMENT | $479,606 |
New Orleans, LA PURPOSE: RESEARCH & DEVELOPMENT | $427,361 |
Grants Recieved
Over the last fiscal year, we have identified 14 grants that International Aids Vaccine Initiative Inc has recieved totaling $41,312,156.
| Awarding Organization | Amount |
|---|---|
Bill & Melinda Gates Foundation Seattle, WA PURPOSE: HIV | $15,850,141 |
Bill & Melinda Gates Foundation Seattle, WA PURPOSE: HIV | $9,149,859 |
Bill & Melinda Gates Foundation Seattle, WA PURPOSE: HIV | $6,108,868 |
Bill & Melinda Gates Foundation Seattle, WA PURPOSE: HIV | $3,154,496 |
Bill & Melinda Gates Foundation Seattle, WA PURPOSE: RESEARCH AND LEARNING OPPORTUNITIES | $2,500,000 |
Bill & Melinda Gates Foundation Seattle, WA PURPOSE: RESEARCH AND LEARNING OPPORTUNITIES | $1,630,787 |
Peer Organizations
| Organization Name | Assets | Revenue |
|---|---|---|
Medecins Sans Frontiers Usa Inc New York, NY | $471,142,331 | $649,355,353 |
Hadassah Medical Relief Association Inc New York, NY | $704,848,131 | $50,906,481 |
Catholic Medical Mission Board Inc New York, NY | $138,995,355 | $411,400,438 |
Project Orbis International Inc New York, NY | $66,731,169 | $230,892,300 |
Vital Strategies Inc New York, NY | $177,082,851 | $109,127,660 |
Management Sciences For Health Inc Medford, MA | $61,343,018 | $145,424,118 |
Pathfinder International Watertown, MA | $89,364,695 | $143,412,954 |
Brothers Brother Foundation Pittsburgh, PA | $16,877,615 | $117,307,567 |
International Aids Vaccine Initiative Inc New York, NY | $107,049,023 | $126,352,598 |
Central European University New York, NY | $577,160,061 | $72,058,098 |
Oxfam-America Inc Boston, MA | $98,567,095 | $108,365,278 |
Helen Keller International New York, NY | $112,029,852 | $121,068,878 |